Chapter review

Fitzgerald PMHNP board review. ch08. Mood Disorders. This is drive 6 of 8. When I say Pause. Answer. wait, then I will give the answer. New section. First-line treatment, monitoring, contraindications, and black box warnings. Topic. Discontinuation Syndrome. Bottom Line Summary. * **Antidepressant discontinuation syndrome** occurs when SSRIs, SNRIs, or TCAs taken continuously for 6 weeks or longer are stopped abruptly or tapered too rapidly. * Symptoms are remembered using the **FINISH** mnemonic: **Flu-like symptoms** (lethargy, fatigue, myalgias), **Insomnia** and vivid dreams, **Nausea** and vomiting, **Imbalance** (dizziness, vertigo, ataxia), **Sensory disturbances** (brain zaps, electric shock sensations), and **Hyperarousal** (anxiety, agitation) or **Headache**. * **Paroxetine** and **venlafaxine** carry the highest risk of discontinuation syndrome due to their short half-lives and lack of active metabolites. * **Fluoxetine** carries the lowest risk of discontinuation syndrome because its long parent half-life of 84 hours and active metabolite **norfluoxetine** half-life of 7 to 15 days create a built-in self-taper. * Symptoms typically emerge within 24 to 72 hours of stopping medication, last less than 7 days to 2 weeks, and are bothersome but not life-threatening. * Prevention requires a gradual dose taper over approximately 6 weeks. If severe withdrawal occurs, reinstate the original medication or switch to **fluoxetine** for a slow taper. * **Safety alert**: Discontinuation syndrome is medically benign and must be distinguished from life-threatening **serotonin syndrome** or severe substance withdrawal. Antidepressant Discontinuation Syndrome Clinical Framework. Pathophysiology and High-Risk Agents. Antidepressant discontinuation syndrome occurs following the abrupt cessation or rapid dose reduction of antidepressants taken continuously for 6 weeks or longer. The abrupt removal of serotonergic or noradrenergic tone causes a transient neurochemical dysregulation in central receptor pathways. **First-line** agents like SSRIs and SNRIs vary significantly in their withdrawal risk based on pharmacokinetic half-life: * Short half-life drugs: **Paroxetine** (SSRI) and **venlafaxine** (SNRI) carry the highest risk of severe discontinuation syndrome. **Venlafaxine** is particularly notorious, often requiring specialized, ultra-gradual tapering schedules such as dissolving capsule contents in water to slowly step down the dose. * Long half-life drugs: **Fluoxetine** has a parent half-life of 84 hours and an active metabolite, **norfluoxetine**, with a half-life of 7 to 15 days. This extended elimination curve provides a natural tapering effect, making **fluoxetine** essentially immune to acute discontinuation syndrome. **Board trap**: Test writers often try to trick candidates into thinking long half-life drugs cause worse withdrawal because they stay in the body longer. The opposite is true. Short half-life agents cause rapid plasma drop-offs and trigger the most severe withdrawal symptoms. Clinical Presentation and the FINISH Mnemonic. Symptoms usually begin within 24 to 72 hours of missing doses or stopping therapy. The clinical presentation is recalled using the **FINISH** mnemonic: * **F**: **Flu-like symptoms** including fatigue, lethargy, malaise, and myalgias. * **I**: **Insomnia** accompanied by vivid, disturbing dreams or nightmares. * **N**: **Nausea**, vomiting, anorexia, or abdominal cramps. * **I**: **Imbalance** including dizziness, lightheadedness, vertigo, and gait ataxia. * **S**: **Sensory disturbances** featuring classic **brain zaps**, paresthesias, electric shock sensations in the head or limbs, and tinnitus. * **H**: **Hyperarousal** including anxiety, irritability, agitation, and **Headache**. **Safety alert**: While discontinuation symptoms are uncomfortable and distressing to the patient, they are not life-threatening and do not cause autonomic collapse, seizures, or organ failure. Tapering and Management Protocols. To prevent discontinuation syndrome, all antidepressants taken for 6 weeks or longer should be gradually tapered over a minimum of 6 weeks. If a patient presents with mild discontinuation symptoms after missing doses, reassure them that symptoms are temporary and will resolve within 1 to 2 weeks. If symptoms are severe: 1. Reinstate the antidepressant at the previously effective dose to achieve rapid symptom relief. 2. Begin a much slower, gradual taper over several months. 3. Alternatively, switch the patient to an equivalent dose of **fluoxetine** and allow its long half-life to provide an automatic, smooth taper as it is discontinued. Compare and Distinguish. Discontinuation Syndrome vs. Serotonin Syndrome. * Think: Discontinuation syndrome is a benign withdrawal state from stopping a drug; **serotonin syndrome** is a toxic, life-threatening emergency from drug excess or combination. * Priority: Reassure and taper for discontinuation syndrome; immediately stop all serotonergic agents and provide emergency supportive care for **serotonin syndrome**. * Boards are testing: Discontinuation features **brain zaps**, dizziness, and flu-like symptoms; **serotonin syndrome** features hyperthermia, autonomic instability, diarrhea, and neuromuscular rigidity. * Classic distractor: Mistaking early discontinuation anxiety and agitation for acute **serotonin syndrome**. Discontinuation Syndrome vs. Major Depressive Relapse. * Think: Discontinuation syndrome onset is rapid (24 to 72 hours) with somatic symptoms; depressive relapse onset is gradual (weeks to months) with psychological symptoms. * Priority: Reinstate or taper medication for discontinuation syndrome; reassess overall treatment plan and consider switching or augmenting for depressive relapse. * Boards are testing: Discontinuation includes unique somatic markers like **brain zaps**, dizziness, and nausea that rapidly resolve upon restarting the drug; relapse presents with persistent anhedonia, low mood, and **SIGECAPS** criteria over weeks. * Classic distractor: Assuming a patient who feels sick 2 days after stopping an SSRI is experiencing an immediate relapse of severe depression. Fitzgerald Board Practice Question Bank. Question 1. Question: SSRI withdrawal syndrome is best characterized as: - A. Potentially life-threatening - B. Bothersome but not life-threatening - C. Most often seen with medications with a longer half-life - D. Associated with seizure risk Pause. Answer: B Why it is correct: Antidepressant discontinuation syndrome causes uncomfortable symptoms such as flu-like feelings, dizziness, brain zaps, and nausea, but it is not life-threatening. Why the other choices are wrong: - A. Discontinuation syndrome is uncomfortable but medically benign, not life-threatening. - B. Correct choice because SSRI withdrawal is bothersome but not life-threatening. - C. It occurs most commonly with short half-life agents like paroxetine or venlafaxine, not long half-life drugs like fluoxetine. - D. Seizure risk is associated with abrupt withdrawal of alcohol or benzodiazepines, not SSRIs. Test-taking pearl: Antidepressant discontinuation syndrome is bothersome but not life-threatening; prevent it by tapering medications over 6 weeks. Concept tested: Antidepressant discontinuation syndrome characteristics Question 2. Question: Which of the following is false when considering discontinuation of treatment for stable major depressive disorder? - A. Psychotherapy has less risk of relapse than psychopharmacotherapy - B. Treatment should be discontinued immediately rather than tapering doses - C. Patients should be educated on signs and symptoms of relapse - D. A follow-up visit should be scheduled two months following cessation of treatment Pause. Answer: B Why it is correct: Antidepressant medications must always be gradually tapered over weeks to avoid discontinuation syndrome; abrupt cessation is unsafe and incorrect. Why the other choices are wrong: - A. True statement; psychotherapy builds durable coping skills and carries lower relapse rates after discontinuation than medication alone. - B. Correct choice because abrupt discontinuation is false and clinically unsafe. - C. True statement; educating patients and families on early relapse signs is essential. - D. True statement; a follow-up visit 2 months after stopping treatment verifies sustained remission. Test-taking pearl: Always taper antidepressants gradually when stopping treatment, and schedule a follow-up appointment within 2 months of complete cessation. Concept tested: Antidepressant discontinuation protocols 💡 **Next Study Step**: Would you like to cover the next leaf on **Pregnancy and Lactation Considerations**, or drill active recall questions on antidepressant half-lives and toxicity profiles? Next. Topic. Advanced Bipolar Management. Bottom Line Summary. * **Acute Mania Monotherapy and Combination**: First-line monotherapy for acute mania includes **lithium**, **valproate** (divalproex), **carbamazepine**, or second-generation antipsychotics (**SGAs**). When rapid control of acute agitation or aggressive behavior is required, **SGAs** are preferred due to a faster onset of action compared to traditional mood stabilizers. * **Symptom Predictors for Mood Stabilizers**: Classic euphoric or grandiose mania responds best to **lithium**. Dysphoric or irritable mania, mixed features, comorbid substance use disorders, or a history of traumatic brain injury responds best to **valproate**. * **Acute Bipolar Depression First-Line Rules**: First-line options for acute bipolar depression include **lithium**, **lamotrigine**, **quetiapine** (dosed specifically at 300 mg daily), **lurasidone**, **lumateperone**, or the **olanzapine-fluoxetine** combination. Antidepressant monotherapy is strictly contraindicated due to the high risk of precipitating acute mania or rapid cycling. * **Suicide Risk Reduction**: **Lithium** and **clozapine** are the only two psychiatric medications proven to independently reduce suicide risk. **Lithium** should be retained in the treatment regimen whenever suicidality is present. * **Lithium Pharmacokinetics and Trough Rules**: **Lithium** is excreted 100% unchanged by the kidneys. Draw a 12-hour post-dose trough level after 4 days of initiation or dose change, as steady state is reached at 5 days. Target therapeutic trough levels are 0.8 to 1.2 mEq/L for acute mania and 0.6 to 1.0 mEq/L for maintenance. * **Lithium Toxicity and Drug Interactions**: Toxicity begins at 1.5 mEq/L and becomes a medical emergency above 2.0 mEq/L. **NSAIDs** (like ibuprofen), **ACE inhibitors** (like lisinopril), **ARBs**, and **thiazide diuretics** decrease renal clearance and cause toxic lithium retention. **Prednisone** does not alter lithium levels. **Lithium** is Hale's Lactation Risk Category L4 (hazardous) and is contraindicated in breastfeeding. * **Valproate and Carbamazepine Safety Parameters**: **Valproate** target serum range is 50 to 120 mcg/mL; discontinue if transaminases (AST and ALT) elevate greater than 2 to 3 times the upper limit of normal. **Carbamazepine** requires mandatory **HLA-B\*1502** genetic screening in patients of Asian ancestry due to a 5% incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis. * **Lamotrigine Dosing Protocol**: **Lamotrigine** requires no baseline laboratory testing prior to initiation. To prevent Stevens-Johnson syndrome, strictly follow the 6-week titration schedule: 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 100 mg daily for 1 week, then 200 mg daily. Advanced Bipolar Management: Clinical and Pharmacological Review. Acute Mania and Mixed Episode Management. `First-line` For acute mania or mixed episodes, first-line monotherapy options include **lithium**, **valproate** (divalproex), **carbamazepine**, or a second-generation antipsychotic (**SGA**). For severe manic presentations or mixed states requiring immediate behavioral control, initiating combination therapy with an **SGA** plus **lithium** or **valproate** is recommended. Short-term high-potency benzodiazepines, such as **clonazepam** or **lorazepam**, can be added as adjunctive agents to target acute agitation, insomnia, hostility, or severe dysphoria. `Safety alert` Antidepressant medications must be tapered and discontinued immediately upon the emergence of manic or hypomanic symptoms. Continuing an antidepressant during a manic phase destabilizes mood further and accelerates cycle frequency. If acute manic symptoms fail to respond after 10 to 14 days of first-line monotherapy, switch to an alternative first-line agent or convert to combination therapy. For severe, life-threatening, or treatment-refractory mania, **ECT** or **clozapine** serves as the definitive intervention. `Board trap` When an exam question describes acute agitation or aggressive behavior in a manic patient, do not wait for the delayed therapeutic onset of a traditional mood stabilizer. Second-generation antipsychotics provide a significantly faster onset of anti-agitation and antimanic effects than **lithium** or **valproate**. Furthermore, tailor the mood stabilizer to the symptom subtype: select **lithium** for classic euphoric or grandiose mania. Select **valproate** for dysphoric or irritable mania, mixed features, comorbid substance use, or a history of traumatic brain injury. Avoid **olanzapine** in patients with obesity or diabetes mellitus. Avoid **lithium** in patients with chronic kidney disease. Acute Bipolar Depression Management. `First-line` First-line monotherapies for acute bipolar depression include **lithium**, **lamotrigine**, **quetiapine** (at a targeted dose of 300 mg daily), **lurasidone**, **lumateperone**, or the fixed combination of **olanzapine** and **fluoxetine**. **ECT** is the primary treatment of choice for severe bipolar depression accompanied by acute life-threatening suicidality, psychosis, or severe depression during pregnancy. `Safety alert` Unipolar antidepressant monotherapy is strictly contraindicated in bipolar depression. Prescribing an **SSRI** or **SNRI** without a concurrent mood stabilizer risks triggering manic conversion or rapid cycling. If fluoxetine is prescribed, it must always be co-prescribed in combination with **olanzapine**. `Board trap` Board exams frequently attempt to trick candidates into discontinuing **lithium** when a patient presents in a depressed phase. Retain **lithium**! **Lithium** possesses proven, independent anti-suicidal properties. Retaining **lithium** maintains suicide prevention while adding targeted depressive treatments such as **lamotrigine**, **quetiapine**, or **lurasidone**. Bipolar Maintenance Therapy and Psychoeducation. `First-line` Maintenance therapy is indicated for all patients diagnosed with bipolar disorder because 90% of individuals experiencing a single manic episode will suffer recurrent mood episodes within 5 years. Uncontrolled recurrent episodes cause progressive cognitive impairment, structural brain changes, and reduced treatment responsiveness in subsequent episodes. First-line maintenance options include **lithium**, **divalproex**, **quetiapine**, **lurasidone**, or long-acting injectable **aripiprazole**. `Safety alert` Individual or group psychoeducation reduces bipolar relapse rates by 25% to 30%. Clinicians must educate patients and family members to recognize early prodromal warning signs of relapse, such as sleep disruption, racing thoughts, or sudden changes in activity levels. `Board trap` Fitzgerald highlights a high-yield clinical strategy known as the "fire drill for mania" protocol. Stable maintenance patients keep a low-dose **SGA** (such as **olanzapine** 5 mg to 10 mg or **quetiapine** 50 mg to 100 mg) at home. At the very first sign of sleep loss or racing thoughts, the patient takes the **SGA** immediately and contacts the NP, preventing full-blown manic hospitalization. Psychotropic Monitoring, Laboratory Baselines, and Toxidromes. `Safety alert` **Valproate** (Divalproex / Depakote): * **Baseline Laboratory Workup**: Liver function panel (AST, ALT, alkaline phosphatase, bilirubin, albumin, total protein), complete blood count with differential and platelet count, and serum hCG. * **Therapeutic Range and Level Monitoring**: Target serum level is 50 to 120 mcg/mL. Check levels monthly during initial titration, and every 6 to 24 months during stable maintenance. * **Hepatotoxicity Rules**: Transaminase elevations (AST and ALT) occur in 2% to 44% of patients, most commonly during the first 6 months. Discontinue **valproate** if AST or ALT elevates greater than 2 to 3 times the upper limit of normal. * **Hematologic Warnings**: Thrombocytopenia and neutropenia are major complications; instruct patients to report unusual bruising, petechiae, or bleeding. * **Boxed Warnings**: Neural tube defects (spina bifida), fatal hepatotoxicity, and pancreatitis. `Board trap` **Carbamazepine** (Tegretol): * **Baseline Laboratory Workup**: Liver panel, complete blood count with differential, and serum hCG. Therapeutic serum level range is 4 to 12 mcg/mL. * **Genetic Screening Mandate**: **Carbamazepine** carries a 5% incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients of Asian ancestry who carry the **HLA-B\*1502** allele. Genetic testing for the **HLA-B\*1502** allele is mandatory prior to starting **carbamazepine** in Asian patients. `Safety alert` **Lithium Carbonate**: * **Baseline Laboratory Workup**: Serum creatinine, BUN, GFR, TSH, serum electrolytes, CBC with differential, serum hCG, urinalysis, and baseline EKG. * **Trough Timing Protocol**: Measure a 12-hour post-dose trough level after 4 days of dosing (steady state is achieved at 5 days), then every 4 to 5 days during acute titration. * **Therapeutic Range**: 0.8 to 1.2 mEq/L for acute mania; 0.6 to 1.0 mEq/L for maintenance. * **Long-Term Monitoring**: Check creatinine, BUN, GFR, TSH, UA, CBC, and 12-hour serum lithium levels every 4 to 8 weeks up to every 6 to 12 months. Repeat EKG every 6 to 12 months in patients over age 50. Reduce the dose if GFR drops below 60 mL/min. * **Toxicity Presentation**: **Lithium** is excreted 100% unchanged by the kidneys and has a narrow therapeutic index. Toxicity manifests at 1.5 mEq/L and becomes a life-threatening emergency above 2.0 mEq/L. Symptoms include lethargy, coarse hand tremor, muscle weakness, cramping, vomiting, diarrhea, blurred vision, confusion, nystagmus, ataxia, hyperreflexia, and cardiac arrhythmias. * **High-Risk Drug Interactions**: **NSAIDs** (such as ibuprofen), **ACE inhibitors** (such as lisinopril), **ARBs**, and **thiazide diuretics** decrease renal excretion and elevate serum lithium to toxic levels. **Prednisone** does not alter lithium levels. * **Lactation Warning**: **Lithium** is Hale's Lactation Risk Category L4 (hazardous) and is contraindicated in breastfeeding due to severe risks of infant toxicity and fluid/electrolyte disruption. `Board trap` **Lamotrigine** (Lamictal): * **Baseline Laboratory Workup**: **Lamotrigine** requires no initial laboratory testing prior to starting therapy. * **SJS Prevention Protocol**: To prevent Stevens-Johnson syndrome rash, strictly follow the slow dose escalation schedule: 25 mg daily for 2 weeks, then 50 mg daily for 2 weeks, then 100 mg daily for 1 week, reaching a target maintenance dose of 200 mg daily. Chapter 8 Practice Questions for Advanced Bipolar Management. Question 4. Jeremy, a 36-year-old married attorney, was referred by his primary care provider for a consultation regarding his depression. He relates problems with what he would call minor depression and mood swings for at least 15 years. He denies ever having any suicidal ideation, hospitalization, or legal difficulty. On the Mood Disorder Questionnaire (MDQ), he checks four items positive and three as possibly positive. Which disorder most likely fits his symptoms? A. Bipolar 1 disorder B. Bipolar 2 disorder C. Cyclothymic disorder D. Dysthymia Pause. Answer: C Keyed Letter: C Why It Is Correct: Cyclothymic disorder is a chronic, fluctuating mood disturbance lasting at least 2 years in adults (15 years in this patient) involving periods of hypomanic symptoms and depressive symptoms that do not meet full criteria for a major depressive or manic episode. The patient functions well as an attorney without suicidal ideation, legal trouble, or psychiatric hospitalizations. Why the Other Choices Are Wrong: * Option A is wrong because Bipolar 1 disorder requires at least one full manic episode, which causes severe functional disruption, psychosis, or emergency hospitalization. * Option B is wrong because Bipolar 2 disorder requires a history of at least one full major depressive episode and at least one clear hypomanic episode. * Option D is wrong because Dysthymia (persistent depressive disorder) consists of chronic low-grade depression without any periods of hypomanic or elevated mood symptoms. Question 5. The patient with bipolar disorder who is most likely to be misdiagnosed as having unipolar depression most likely has: A. Dysthymia B. Bipolar type 2 C. Bipolar type 1 D. Cyclothymia Pause. Answer: B Keyed Letter: B Why It Is Correct: Patients with Bipolar type 2 disorder spend the vast majority of their symptomatic lifetime in major depressive episodes and seek treatment exclusively while depressed. They rarely report hypomania because hypomanic episodes feel pleasant, energetic, and productive, leading patients to omit hypomanic histories unless systematically screened. Why the Other Choices Are Wrong: * Option A is wrong because Dysthymia is a primary unipolar depressive disorder rather than a bipolar spectrum diagnosis. * Option C is wrong because Bipolar type 1 features distinct manic episodes that cause severe behavioral disruption, psychosis, or emergency hospitalization, making the manic history obvious and reducing misdiagnosis. * Option D is wrong because Cyclothymia consists of low-grade fluctuating mood shifts that do not meet criteria for full major depressive episodes. Question 9. There is positive evidence that the use of lithium by a breastfeeding woman can pose a risk to the infant. This medication meets Hale's lactation risk category: A. L1 B. L2 C. L3 D. L4 Pause. Answer: D Keyed Letter: D Why It Is Correct: **Lithium** is classified under Hale's Lactation Risk Category L4 (hazardous). **Lithium** is excreted in high concentration into breast milk, posing severe risks of renal impairment, fluid/electrolyte toxicity, and central nervous system depression in the nursing infant. Why the Other Choices Are Wrong: * Option A is wrong because Category L1 represents the safest drugs with extensive controlled studies showing no infant risk. * Option B is wrong because Category L2 represents safer drugs tested in a limited number of women without demonstrated infant risk (such as most SSRIs). * Option C is wrong because Category L3 represents moderately safe drugs lacking controlled data where potential benefits may justify potential risks. Question 18. Mr. Cooper is treated for bipolar disorder with lithium carbonate. His last lithium level was 0.7 mEq/L. Which of the following is NOT a risk factor for developing lithium toxicity? A. Ibuprofen 600 mg daily for joint pain B. Addition of lisinopril to blood pressure regimen C. A change in GFR less than 60 mL/min per 1.73 m squared D. Addition of prednisone for the management of an acute gout attack Pause. Answer: D Keyed Letter: D Why It Is Correct: **Prednisone** is a corticosteroid that does not decrease renal lithium clearance or alter renal tubular transport, meaning it does not cause toxic lithium accumulation and can be safely prescribed during acute inflammatory flares. Why the Other Choices Are Wrong: * Option A is wrong because **ibuprofen** is an NSAID that inhibits renal prostaglandin synthesis, decreasing renal blood flow and lithium clearance, which rapidly precipitates lithium toxicity. * Option B is wrong because **lisinopril** is an ACE inhibitor that alters glomerular filtration mechanics, causing toxic accumulation of lithium. * Option C is wrong because a decline in GFR below 60 mL/min impairs renal excretion, leading to dangerous serum lithium retention because lithium is 100% excreted unchanged by the kidneys. Question 20. Which of the following medications does not require initial laboratory testing before implementing therapy? A. Carbamazepine B. Lamotrigine C. Valproate D. Lithium Pause. Answer: B Keyed Letter: B Why It Is Correct: **Lamotrigine** requires no baseline blood tests or organ function laboratory monitoring before initiating therapy. Clinical safety depends entirely on adhering strictly to the slow 6-week dose titration protocol to minimize Stevens-Johnson syndrome risk. Why the Other Choices Are Wrong: * Option A is wrong because **carbamazepine** requires baseline LFTs, CBC with differential, serum pregnancy testing, and mandatory **HLA-B\*1502** genetic screening in Asian patients. * Option C is wrong because **valproate** requires baseline LFTs, CBC with differential and platelets, and serum pregnancy testing prior to initiation. * Option D is wrong because **lithium** requires comprehensive baseline testing including serum creatinine, BUN, GFR, TSH, electrolytes, CBC, urinalysis, serum pregnancy test, and baseline EKG. 💡 *Next Study Step*: Review **Fitzgerald Chapter 9: Anxiety Disorders**, focusing on Generalized Anxiety Disorder, Panic Disorder, and PTSD, mastering first-line SSRI/SNRI dosing, and recognizing benzodiazepine safety boundaries. Next. New section. Medical rule-outs, suicide risk, peripartum/special populations, and board traps. Topic. Medical Mimics and Rule-outs. Bottom Line. - Always rule out physical medical conditions, lab abnormalities, and substance or medication effects before assigning a primary diagnosis of **major depressive disorder** or **bipolar disorder**. - Depressive symptoms caused by a substance or prescribed medication typically remit within 1 month of discontinuing the offending agent. - Post-stroke depression occurs frequently in medical inpatients and cerebrovascular populations, with symptom onset typically developing weeks to months following a cerebrovascular accident (CVA). - Steroids like **prednisone** and central nervous system stimulants can induce manic or depressive symptoms. If full manic criteria persist beyond the expected physiological effect of the drug, the diagnosis becomes primary **bipolar I disorder**. - Medical inpatients experience a 15% higher prevalence of **major depressive disorder** compared to the general population. - In neurodegenerative conditions such as Parkinson's disease and Huntington's disease, mood symptoms and depression frequently precede motor impairments. - **Lithium** levels are elevated by NSAIDs like **ibuprofen**, ACE inhibitors like **lisinopril**, thiazide diuretics, and a GFR below 60 mL/min/1.73 m2, whereas **prednisone** causes mood alterations without altering **lithium** serum clearance. Must Know for Boards. Differential Diagnosis and Organic Causes. - **First-line** clinical priority: Always perform a comprehensive physical evaluation and baseline lab panel (CBC, CMP, TSH, B12, hCG, urine drug screen) to rule out medical mimics before diagnosing a primary psychiatric disorder or initiating psychotropics. - **Safety alert**: Hypothyroidism (elevated TSH) directly mimics unipolar depression, whereas hyperthyroidism or steroid therapy can precipitate manic or hypomanic symptoms. Always assess TSH before diagnosing unipolar depression or escalating antidepressant therapy. - Neurologic conditions including stroke (CVA), Multiple Sclerosis, Parkinson's disease, and Huntington's disease directly cause mood alterations. Post-CVA depression typically manifests weeks to months after the vascular event. - **Board trap**: Assuming new-onset depressive or manic symptoms in an older adult or medically complex patient are purely psychiatric. Medical inpatients carry a 15% higher risk of **major depressive disorder**, and general medical comorbidities significantly elevate the 50% to 85% lifetime recurrence risk of MDD. Medication- and Substance-Induced Mood Disorders. - Substance or medication-induced depressive disorder requires that mood symptoms develop during or soon after substance exposure, intoxication, or withdrawal, extending beyond expected acute physiological effects. Symptoms usually resolve within 1 month of stopping the substance. - Common medication causes of depressive symptoms include beta-blockers, interferon, corticosteroids (**prednisone**), and central nervous system depressants. - **Safety alert**: If full manic criteria emerge during **prednisone** or antidepressant therapy and persist at a full syndromal level beyond the expected drug clearance window, the formal diagnosis becomes primary **bipolar I disorder**. - **Board trap**: Confusing drug interactions that elevate **lithium** toxicity with drugs that cause psychiatric mimics. **Ibuprofen**, **lisinopril**, thiazide diuretics, and a GFR under 60 mL/min/1.73 m2 impair renal elimination and trigger **lithium** toxicity. Conversely, **prednisone** causes psychiatric side effects like hypomania or agitation, but it does not alter **lithium** blood levels. Compare and Distinguish. Substance or Medication-Induced Depressive Disorder vs. Major Depressive Disorder Due to Another Medical Condition - Think: Exogenous drug trigger versus underlying organ pathology. - Priority: Discontinue or taper the offending medication versus treating the underlying physical disease. - Boards are testing: Diagnostic timelines and resolution. Substance-induced mood symptoms resolve within 1 month of drug cessation, whereas depression due to CVA, Parkinson's, or hypothyroidism persists until the physical medical condition is treated. Bipolar Type II Misdiagnosis vs. Unipolar Major Depressive Disorder - Think: Unrecognized hypomanic history versus true unipolar depression. - Priority: Conduct thorough longitudinal screening to uncover past hypomanic blips. - Boards are testing: **Bipolar II disorder** is the most common bipolar spectrum condition misdiagnosed as unipolar MDD because patients seek treatment during depressive phases and rarely report hypomania. Sample Board Practice Questions. Question 1. A 56-year-old woman with a history of hypertension and asthma presents to the clinic complaining of new-onset depressed mood, severe fatigue, and anhedonia for the past 3 weeks. She was recently started on a new medication for her asthma flare-up. Which of the following statements regarding medication-induced depressive disorders is correct? - A. Symptoms are expected to persist indefinitely even after stopping the offending medication. - B. Depressive symptoms usually remit within 1 month of discontinuing the offending substance or medication. - C. A primary diagnosis of major depressive disorder should be assigned immediately without stopping the drug. - D. Antidepressant monotherapy is the initial treatment of choice while continuing high-dose systemic steroids. Pause. Answer. B. Why it is correct: Substance or medication-induced depressive disorders are characterized by mood symptoms caused by a drug or toxin that usually resolve within 1 month following cessation of the substance. Why the other choices are wrong: - A. Incorrect because medication-induced depressive symptoms typically resolve after the drug is cleared rather than persisting indefinitely. - B. Correct rationale as stated above. - C. Incorrect because medical and medication causes must be ruled out or addressed before establishing a primary major depressive disorder diagnosis. - D. Incorrect because the initial step is to re-evaluate or discontinue the offending medication rather than adding unneeded psychotropics. Question 2. Mr. Cooper is a 48-year-old man being treated for **bipolar I disorder** with **lithium** carbonate, with a recent therapeutic serum level of 0.7 mEq/L. He presents to the clinic with a mild respiratory condition and acute joint pain. Which of the following medications or clinical changes is NOT a risk factor for developing **lithium** toxicity? - A. **Ibuprofen** 600 mg daily for joint pain - B. Addition of **lisinopril** to his blood pressure regimen - C. A decrease in GFR to less than 60 mL/min/1.73 m2 - D. Addition of **prednisone** for the management of an acute inflammatory flare Pause. Answer. D. Why it is correct: **Prednisone** is a corticosteroid that can cause mood changes or manic symptoms, but it does not alter renal clearance or increase serum **lithium** levels. Why the other choices are wrong: - A. Incorrect choice to select because NSAIDs like **ibuprofen** decrease renal blood flow and increase **lithium** reabsorption, significantly raising toxicity risk. - B. Incorrect choice to select because ACE inhibitors like **lisinopril** decrease **lithium** clearance and trigger toxicity. - C. Incorrect choice to select because **lithium** is excreted almost 100% unchanged by the kidneys; a drop in GFR below 60 mL/min/1.73 m2 impairs clearance and causes toxic accumulation. - D. Correct answer because **prednisone** does not cause **lithium** toxicity through pharmacokinetic interactions. Question 3. A 22-year-old male with type 1 diabetes mellitus and generalized anxiety disorder is currently being treated for **major depressive disorder**, recurrent. He has been symptom-free for 6 months on **sertraline** and asks if he can discontinue his medication. You counsel him that he has a high risk of depressive recurrence due to which of the following factors? - A. Past history of multiple depressive episodes - B. Presence of a co-occurring chronic medical condition - C. Co-occurring generalized anxiety disorder - D. All of the above Pause. Answer. D. Why it is correct: Recurrence risk in **major depressive disorder** is significantly increased by a history of recurrent episodes, presence of co-occurring general medical conditions (like type 1 diabetes), co-occurring non-affective psychiatric disorders (like GAD), and younger age of onset. Why the other choices are wrong: - A. Incorrect as a single selection because while past recurrent episodes increase risk, choices B and C are also established risk factors. - B. Incorrect as a single selection because chronic medical conditions contribute independently to recurrence risk alongside psychiatric comorbidities. - C. Incorrect as a single selection because co-occurring anxiety disorders elevate relapse risk, making all options collectively correct. - D. Correct answer because all listed factors independently increase the risk of depression recurrence. Question 4. Which patient with a bipolar spectrum disorder is most likely to be misdiagnosed as having unipolar **major depressive disorder**? - A. Dysthymia - B. **Bipolar II disorder** - C. **Bipolar I disorder** - D. Cyclothymic disorder Pause. Answer. B. Why it is correct: Patients with **bipolar II disorder** present during major depressive episodes and rarely report hypomanic blips, leading clinicians to misdiagnose them with unipolar depression. Why the other choices are wrong: - A. Incorrect because dysthymia (persistent depressive disorder) is a chronic low-grade unipolar depressive condition without hypomanic or manic history. - B. Correct answer as stated above. - C. Incorrect because **bipolar I disorder** involves overt manic episodes that cause marked impairment or hospitalization, making recognition obvious. - D. Incorrect because cyclothymic disorder involves fluctuating hypomanic and depressive symptoms that do not meet full criteria for a major depressive episode. Question 5. A 36-year-old married attorney presents for a psychiatric consultation complaining of minor depression and chronic mood swings for 15 years. He denies any history of suicidal ideation, psychiatric hospitalizations, or legal difficulties. On screening, he checks several items positive for mild hypomanic symptoms and low-grade depressive periods. Which diagnosis most likely fits his presentation? - A. **Bipolar I disorder** - B. **Bipolar II disorder** - C. Cyclothymic disorder - D. Dysthymia Pause. Answer. C. Why it is correct: Cyclothymic disorder is a chronic cyclic mood disturbance lasting at least 2 years in adults (1 year in children) with numerous periods of hypomanic symptoms and depressive symptoms that do not meet full criteria for manic, hypomanic, or major depressive episodes. Why the other choices are wrong: - A. Incorrect because **bipolar I disorder** requires at least one full manic episode causing severe impairment or hospitalization. - B. Incorrect because **bipolar II disorder** requires at least one full major depressive episode alongside a distinct hypomanic episode. - C. Correct answer as stated above. - D. Incorrect because dysthymia involves chronic depressed mood without periods of hypomanic symptoms. 💡 Would you like to review suicide risk assessments, peripartum mood management, or move on to Chapter 9 (Anxiety Disorders)? Next. End of this drive.